GRACE :: Lung Cancer

Challenging Cases in Lung Cancer: Stage IIIA N2 Node-Positive NSCLC, Debatably Resectable

download as a pdf file Download PDF

As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lung cancer discussed with multiple experts, here’s one on the common but vexing scenario of a patient with mediastinal node-positive (stage IIIA N2) NSCLC. This is among the most controversial clinical settings in lung cancer, as illustrated by the wide range of answers of how the experts in this program would manage the same patient. Some of the experts even note that the way that such a patient would be managed at their center would depend on the people weighing in on the case. This also underscores how important a multidisciplinary approach, often developed in a “tumor board” conference, is for developing treatment plans, ideally by a consensus among the various medical specialists involved.

Here’s the audio podcast, video podcast, and transcript for the program (really not much video to follow for this one).



We’d love to hear your comments and questions.

There are still several more interesting cases in this series, but we’ll take a break from them for a while to bring you the podcasts for the ASCO Lung Cancer Highlights webinar from a couple of weeks ago. Look for those over the next couple of weeks.

And thanks again to LUNGevity Foundation for their support in developing the case series, the ASCO highlights program, and the podcasts for all of these activities!

2 Responses to Challenging Cases in Lung Cancer: Stage IIIA N2 Node-Positive NSCLC, Debatably Resectable

  • DianaJ says:

    I had a severe adverse reaction five hours after xgeva injection April 14 2011; back pain and vomiting. I ended up in ER to get pain and zofran iv. Discontinued xgeva and started chemo april 21.Now I have completed my 4th cycle of carbon/taxol and am looking to start Zometa and lucanix trial. Are there reasons not to do these two immune directed treatments concurrently?

  • Dr West says:

    I don’t think of Zometa as being particularly immune-mediated. Regardless, I don’t believe there is any reason to suspect any significant interaction or contraindication to pursuing these two approaches concurrently.

    -Dr. West

Leave a Reply

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content


Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Other Resources